Isoforms
The multimeric nature of CaMKII allows its activation to be graded by changes in intracellular calcium. The four known isoforms of CaMKII (␣, ␤, ␦, ␥) are encoded by separate genes. ␣ and ␤-CaMKII are the predominant neuronal isoforms, whereas the ␦ and ␥ isoforms are expressed in diverse tissues including the heart (62) . In heart, the predominant isoform is ␦ (23). Although these different isoforms have similar core structures, they differ subtly in their response to Ca 2+ activation in vitro (17). This suggests that each isoform has evolved to decode Ca 2+ oscillations differently, depending on in which cell system they reside. Different splice variants of these isoforms add further diversity to CaMKII input-output characteristics. One splice variant of the ␦ isoform (␦ B or ␦ 3 ) has a nuclear localization signal in the hypervariable region (between the regulatory and association domains), resulting in nuclear targeting (60) . Subcellular targeting of CaMKII is likely to be important for assignment of signal function.
Monomeric structure
The CaMKII monomer consists of an NH 2 -terminal catalytic domain, a centrally located regulatory domain, and a COOH-terminal association domain (FIGURE 1A). The catalytic domain is sufficient to catalyze the transfer of the ␥ phosphate from ATP to serine or threonines embedded within a CaMKII consensus motif (12) . Predicted CaMKII phosphorylation consensus motifs generally follow the form R-X-X-S/T. The regulatory domain contains a pseudosubstrate sequence that, under basal conditions, binds and constrains the catalytic domain. Also located in the regulatory domain is a calmodulin (CaM) binding domain. The pseudosubstrate sequence is built around an activating "autophosphorylation" site at Thr 286/287 (the precise numbering is isoform dependent) (56) and a recently identified activating oxidation site (Met 281 /Met 282 ) (24). Phosphorylation of Thr 286 or oxidation of Met 281 and Met 282 prevents re-association of the catalytic and regulatory domains even after dissociation of CaM, thereby converting CaMKII into a Ca 2+ /CaM-independent signal. An inhibitory autophosphorylation site, Thr 306/307, overlaps with the Ca 2+ -CaM binding sequence. Phosphorylation of Thr 306 is inhibitory because it prevents CaM binding (14) . Oxidation of a lone Met at position 308 also abrogates CaM trapping (24), suggesting that adductive modifications in the COOH-terminal region of the regulatory domain reduce the avidity of CaM binding. Under resting conditions, basal phosphorylation occurs preferentially at Thr 306 , preventing Ca 2+ /CaM binding, resulting in decreased CaMKII activity. This inhibitory autophosphorylation provides a form of feedback regulation of the kinase that is dependent on basal/resting intracellular Ca 2+ levels (14) and perhaps the intracellular redox state (24). Posttranscriptional mechanisms for regulating CaMKII activity are further discussed below. The association domain is responsible for the assembly of CaMKII monomers into the holoenzyme. A variable/hypervariable region, the product of alternative splicing, is located between the regulatory and association domain and may include a nuclear localization sequence (60) . (15, 38, 58) . Calcified CaM binds to the regulatory domain, inducing a conformational change that frees the catalytic domain from its pseudosubtrate (43) . The allosteric rearrangement of CaMKII on binding Ca 2+ /CaM allows ATP access to the ATP binding pocket, which in turn allows CaMKII to catalyze the transfer of a phosphate donor group to downstream targets, including itself (i.e., autophosphorylation). Autophosphorylation, which occurs by an intraholoenzyme reaction (41) , has several important implications for CaMKII activity. First, Thr 286/287 autophosphorylation results in a 1,000-fold increase in the affinity of CaM-CaMKII binding, a property known as "CaM trapping" (46) . Second, autophosphorylation results in the ability of the kinase to maintain catalytic activity even in the absence of CaM binding (56) . Phosphorylation at Thr 306 provides a negative regulatory mechanism for titering CaMKII activity. Under resting conditions, phosphorylation occurs preferentially at Thr 306 , preventing Ca 2+ /CaM binding, which in turn results in decreased CaMKII activity. This inhibitory autophosphorylation provides a form of feedback regulation of the kinase that is dependent on basal/resting intracellular Ca 2+ levels (14) .
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REVIEWS
Recently, a novel form of reactive oxygen species (ROS)-mediated CaMKII activation has been described. These data suggested that CaMKII activation may be more complex than previously realized, potentially indicating that CaMKII is a nodal signal for integrating cellular Ca 2+ and ROS into downstream responses.
Our group recently mapped a pathway for activation and conversion of CaMKII␦ into a Ca 2+ /CaM-independent species by oxidation of paired Met residues (Met 281/282 ) in the regulatory domain (24). These Met residues are oxidized by angiotensin II stimulation and generation of ROS by NADPH oxidase in myocardium. Met oxidation prevents inhibitory reassociation of the catalytic and regulatory domains, much like Thr 286/287 autophosphorylation, but Met 281/282 oxidation and Thr 286/287 autophosphorylation are independent events. In contrast to autophosphorylation, Met oxidation does not result in CaM trapping due to simultaneous oxidation of Met 308 located near the negative regulatory residue Thr 306 . A Met 308Val CaMKII␦ mutant was activated by oxidation and exhibited CaM trapping similar to Thr 286/287 autophosphorylation. These data suggest that activating and inhibitory Met residues are readily available to oxidation. Met oxidation is specifically reversed by Met sulfoxide reductase A (MsrA) (68) . Mice null for MsrA showed higher levels of oxidized CaMKII in myocardium after angiotensin II stimulation or after myocardial infarction compared with controls. MsrA -/-mice had worse myocardial dysfunction and increased mortality after pathological stress. Taken together, these findings show that CaMKII is dually activated by "upstream" Ca 2+ and oxidative signals and that both phosphorylation and Met oxidation are dynamically reversible events.
CaMKII Activation: Cellular Mechanisms
The cardiac action potential plays an important role in mediating CaMKII activation (FIGURE 2). The ventricular cardiomyocyte action potential duration (APD) lasts several hundred milliseconds, approximately two orders of magnitude longer than neuronal action potentials. The prolonged cardiac APD is due to a long plateau phase (so called phases 2 and 3) that is a balance of inward currents (mostly L-type Ca 2+ current) and repolarizing outward currents (mostly K + ). This prolonged plateau phase of the cardiac action potential is critical for allowing Ca 2+ entry, mainly through voltage-gated L-type Ca 2+ current (I Ca ), and limiting cell membrane excitability by imposing a prolonged electrical refractory period. CaMKII activation is enhanced by APD prolongation because the intracellular Ca 2+ transient lengthens in step with APD prolongation (74) . In cardiomyocytes, CaMKII activity appears to be increased by APD prolongation (5) and faster heart rates (67). Langendorff-perfused hearts treated with the K + channel blocker clofilium exhibit APD prolongation and increased Ca 2+ /CaM-independent activity compared with control hearts paced at the same frequency (5) . Increasing the pacing frequency of Langendorff-perfused hearts has also been demonstrated to result in increased Thr 287 autophosphorylation and CaMKII activity (67) . In contrast, the gradation of CaMKII activity is dependent primarily on changes in stimulation frequency in neurons where the dynamic range of APD is more limited.
The dependence of CaMKII activation on pulse duration and frequency has been demonstrated in vitro. When CaMKII is stimulated by shorter Ca 2+ pulse durations (80 ms), it requires higher frequency oscillations (10 Hz) to achieve increased Ca 2+ -autonomous activity. On the other hand, longer Ca 2+ pulse durations (1,000 ms) respond to lower stimulation frequencies (0.8 Hz) to achieve the same level of Ca 2+ and CaM-autonomous activation (17). These in vitro findings not only have implications for the normal physiological effects of APD on CaMKII duration but also suggest a mechanism of excess CaMKII activation in genetic (long QT syndrome) and structural heart disease with APD prolongation (5, 73) . Although stimulation frequency and pulse duration are the best understood upstream regulators of CaMKII activation (17), other factors such as redox potential, CaMKII isoform distribution, phosphatase activity, and intracellular localization also likely participate in determining CaMKII activity in cardiomyocytes.
In heart failure, abnormal Ca 2+ handling can in part be explained by prolongation of APD due to remodeling of ionic currents (10, 48 
REVIEWS FIGURE 2. Action potential duration and CaMKII activity
A: action potential schematic. Because CaMKII activation is dependent on changes in intracellular calcium concentration, changes in action potential duration affect the degree of CaMKII activation. The normal action potential consists of a depolarization phase that is predominantly mediated by inward Na current (phase 0). Phases 2 and 3 of the action potential are primarily mediated by inward calcium current and outward potassium current. Phases 2 and 3 allow for sufficient calcium entry necessary for normal excitation contraction coupling. Long QT syndromes and structural heart disease (i.e., heart failure) are associated with prolongation of the action potential, which is due to electrical remodeling, including decreased potassium current and excess sodium and calcium current. This prolongation results in excess calcium entry into the cardiomyocyte, which results in hyperphosphorylation of CaMKII. (86) that are mediated at least in part by excess CaMKII activation.
Excess CaMKII activity itself can promote APD prolongation in part through a posttranslational mechanism. CaMKII induces L-type Ca 2+ channels (LTCCs) to enter a highly active gating mode marked by frequent, long openings (20). CaMKII is responsible for dynamically increasing I Ca , a phenomenon termed facilitation (4, 77, 82) . CaMKII can also increase APD by a phosphorylation-dependent increase in a noninactivating component of cardiac Na current (I Na ) (64) . Both I Ca and I Na increase net inward current during the AP plateau leading to APD prolongation. CaMKII overexpression leads to cardiomyopathy and heart failure with APD prolongation that may be at least partially due to reduced expression of repolarizing K + currents (44) . Mice with CaMKIV overexpression have coordinate increases in CaMKII expression and activity and show APD prolongation due to reduced repolarizing K + currents (76) . In contrast, CaMKII inhibition shortens the APD and cellular Ca 2+ transient in surviving myocardium after infarction (85) and leads to APD shortening by augmenting the fast component of the transient outward and the inwardly rectifying K + currents by an incompletely characterized nontranscriptional mechanism (42) . Taken together, these findings show that CaMKII sculpts the cardiac APD by a number of mechanisms that appear to be important for the proarrhythmic electrical remodeling phenotype that is a common feature in myocardial hypertrophy and heart failure.
Excessive APD prolongation and increased CaMKII activity predispose to early afterdepolarizations (EADs) by I Ca facilitation and high LTCC activity (73, 76, 83) . APD prolongation leads to CaMKII activation (5), increased sarcoplasmic reticulum Ca 2+ loading, and activation of the delayed afterdepolarization (DAD)-initiating transient inward current (74) . EADs and DADs are depolarizing oscillations in the cell membrane potential that are the probable initiating cause for many arrhythmias, including atrial fibrillation and ventricular arrhythmias in heart failure (53) (FIGURE 3).
Cellular Localization
The structure of CaMKII not only serves to decode Ca 2+ frequency, it also serves to target the kinase directly to key regulatory proteins involved in Ca 2+ homeostasis. Proper targeting of kinases and phosphatases to protein substrates is essential for maintaining signaling fidelity (51 remodeling in heart failure may be initially adaptive by favoring cellular Ca 2+ entry and restoration of contractility. However, these changes are ultimately maladaptive and promote dysregulation of Ca 2+ homeostasis (11) and worsening of cardiac function REVIEWS FIGURE 3. CaMKII and normal excitation contraction coupling A: CaMKII mediates the activity of the LTCC and RyR via phosphorylation-dependent events, which are integral for normal excitation contraction coupling. When a cardiomyocyte is depolarized by a propagating action potential, calcium enters the cell via the LTCC. This initial calcium entry activates the ryanodine receptor, resulting in release of calcium from the SR by a process termed calcium-induced calcium release. Release of calcium from the SR accounts for the majority of intracellular calcium necessary for contractility and other functions of the cardiomyocyte. The majority of cytosolic calcium is removed by SERCA, which is negatively regulated by PLN. The return of cytosolic calcium to basal levels signals the beginning of diastole. B: effect of excess CaMKII activity on excitation contraction coupling. Structural heart disease is associated with excess CaMKII activity. This excess CaMKII activity results in hyperphosphorylation of the LTCC, RyR, and SERCA/PLN, which impairs cardiac functions and predisposes to afterdepolarizations. Hyperphosphorylation of the LTCC at the ␤-subunit results in increased I Ca , which can predispose to EADs (which occur at phases 2 and 3 of the action potential). Hyperphosphorylation events at the SR results in depletion of SR calcium stores, which results in impaired cytosolic calcium transients resulting in systolic and diastolic dysfunction. Furthermore, hyperphosphorylation of the RyR results in SR calcium leak that can result in a net inward Na current via NCX that result in delayed afterdepolarizations (that occur after completion of repolarization). ventricular myocytes where it co-localizes with LTCCs and ryanodine receptors (21, 73). CaMKII binds directly to the NMDA receptor NR2B subunit after phosphorylation of Thr 286 (8, 61) . In adrenal cells, CaMKII directly binds with the intracellular loop of Ttype Ca 2+ channels, regulating channel function by phosphorylation of Ser 1198 (81) . CaMKII also binds the LTCC (CaV1.2) ␣ 1C subunit at multiple sites, including the COOH terminus (35). Thus CaMKII selectively adapts to protein targets in a regulated manner in cardiomyocytes.
We recently identified a CaMKII binding sequence in an auxiliary LTCC ␤ subunit (␤ 2a ) (29). CaMKII binding to the ␤ subunit and to NR2B occurs by way of a sequence that resembles the CaMKII regulatory domain. Thr 286 autophosphorylation enables CaMKII binding to the ␤ subunit and NR2B. On the other hand, phosphorylation of T498 on the ␤ subunit reduces CaMKII-␤ subunit binding. The identification of a CaMKII-specific binding sequence in these important Ca 2+ homeostatic proteins shows that CaMKII adapter sequences (CaMkaps) are embedded in at least some CaMKII substrate targets rather than existing as distinct proteins. These findings suggest that CaMKII targeting may work by a parsimonious (i.e., no requirement for adapter proteins) and novel mechanism. CaMKII inhibitory peptides that mimic the autoinhibitory sequence (59, 85) are thus also anticipated to prevent normal targeting of CaMKII to substrates and so may lead to suppression of CaMKII activity by two distinct mechanisms.
CaMKII and Excitation Contraction Coupling
The excitation-contraction coupling (ECC) apparatus is the mechanism for myocardial mechanical function. CaMKII regulates many of the key proteins for ECC. There is an increasing awareness that disorders of ECC are also the basis for many arrhythmias and can lead to cardiac hypertrophy and heart failure. The joint dependence of myocardial mechanical and electrical functions on ECC provides a rationale for understanding why patients with heart failure (i.e., a clinical condition of inadequate mechanical cardiac function) are also at most risk for arrhythmias and sudden death. CaMKII is now known to contribute to cardiac hypertrophy, heart failure, and arrhythmias, and CaMKII activity and expression are increased in failing human hearts and animal models of structural heart disease (87). The following text will briefly discuss the role of CaMKII at some key ECC proteins.
L-type Ca 2+ channels
LTCCs serve as the primary entry point for Ca 2+ into cardiomyocytes. The predominant ventricular LTCC ␣ subunit (Ca V 1.2) belongs to a family of six membranespanning, voltage-gated channels. Activation of the channel occurs by cell membrane depolarization However, gradation of I Ca is mediated by CaM and CaMKII signaling events. Ca 2+ /CaM can act directly to accelerate channel inactivation. Ca 2+ /CaM, in turn, can activate CaMKII, resulting in augmentation of I Ca , a process termed I Ca facilitation (72) .
CaMKII binds the cytoplasmic COOH terminus of Cav1.2 (35), as well as the ␤ subunit (29), which associates with Cav1.2 at the intracellular I-II linker domain (84) . Early studies demonstrated ablation of I Ca facilitation using pharmacological and peptide inhibitors of CaMKII (4, 77, 82 (79) . It is unknown whether these sites interact. Ca V 1.3 is an LTCC that is present in atrium, cardiac pacemaker cells, and the specialized conduction system. CaMKII may increase Ca V 1.3 by phosphorylating a Ser residue that is present in an intracellular COOH terminal EF hand domain (26). Both Ca V 1.2 and Ca V 1.3 share a homologous EF hand, but the Ser and predicted CaMKII consensus motif are only present in Ca V 1.3. The potential physiological and disease consequences of CaMKII regulation of Ca V 1.3 in heart are unexplored.
Ryanodine receptor
CaMKII co-localizes with the ryanodine receptor (RyR) and the LTCC, poising it to mediate Ca 2+ induced Ca 2+ release (73) . The RyR, located on the sarcoplasmic reticulum (SR) membrane, is juxtaposed with the sarcolemmal LTCC in highly organized SR Ca 2+ release units known as couplons (25). Calcium entry via the LTCC results in activation and release of SR Ca 2+ from the RyR, a process termed Ca 2+ -induced Ca 2+ release. In human and animal models of heart failure, the RyR becomes hyperphosphorylated (2, 45) tive, FDAR promotes acceleration of myocardial relaxation (diastolic function) for the maintenance of efficient ventricular filing at higher heart rates, despite a decreased diastolic time interval. The ability of CaMKII to detect changes in intracellular Ca 2+ as well as to promote SERCA activity by phosphorylating PLN makes it a strong candidate for mediating FDAR.
In isolated ventricular myocytes, it has been shown that Thr 17 phosphorylation and FDAR increase with increasing stimulation frequency, independent of Ser 16 phosphorylation (30). It also has been demonstrated that Thr 17Ala mutation attenuates FDAR at higher pacing frequencies compared with wild-type and Ser 16Ala mutation mouse cardiomyocytes (89). CaMKII inhibition suppresses FDAR (7, 18) . In contrast to these findings, PLN knockout mice still exhibit FDAR, which can be ablated with CaMKII inhibition (18). Furthermore, other studies have demonstrated that Ser 16 is sufficient for mediating ␤-adrenergic receptormediated FDAR (13) . These data support CaMKII as an important mediator of FDAR but do not resolve the controversy about the identity of the key proteins that underlie FDAR. The effects of CaMKII and PLN appear to wane at high (physiological) steady-state frequencies (69), suggesting that modulatory effects of CaMKII on PLN (or alternative FADR mediators) may be most important at slower, irregular stimulation frequencies.
CaMKII inhibition in transgenic mice has been shown to be cardioprotective against chronic ␤-adrenergic receptor (␤AR) stimulation, in part by protecting against SR Ca 2+ overload (85) . This protective effect and the protection against SR Ca 2+ overload are dependent on decreased CaMKII-mediated phosphorylation of PLN (75) . Crossing of CaMKII inhibitory mice with PLN knockouts abolished the resistance to ischemic stress-induced apoptosis by CaMKII inhibition (80) . These findings suggest that PLN is an important molecular determinant for the anti-apoptotic actions of CaMKII inhibition.
CaMKII Inhibition as a Therapeutic Target
In the United States, 280,000 patients die of heart failure annually (55) . With a risk of sudden cardiac death six to nine times that of the general population, about half of heart failure patients die of ventricular arrhythmias. Although drugs that inhibit the adrenergic and renin-angiotensin aldosterone systems have improved survival (1, 1, 49, 52 ), deaths from heart failure increased 28% from 1994 to 2004. Treating arrhythmias in patients with structural heart disease by ion channel antagonist drugs does not reduce mortality (22, 65) . These data support the importance of finding suitable agents for treating both heart failure and arrhythmias.
Pharmacological approaches that inhibit G pro- (Ca 2+ sparks), which may contribute to impaired contractility, promote DADs, and activate cardiomyopathic gene programs. The RyR is a 2.5-MDa intracellular Ca 2+ release channel that consists of four identical subunits. The majority of this channel serves as a cytoplasmic scaffold for myriad accessory proteins, including CaMKII. CaMKII directly binds and phosphorylates RyR at Ser 2809 and Ser 2815 (16, 67, 70) . However, phosphorylation studies suggest CaMKII may phosphorylate additional sites, known and unknown (54) .
Under different experimental conditions, CaMKII has been shown to either increase or decrease Ca 2+ release via the RyR (39, 44, 67, 71, 78) . Isolated RyRs placed in lipid bilayers demonstrate increased CaMKIImediated phosphorylation (Ser 2815 ) and channel activity at increasing heart rates, which are associated with increased CaMKII autophosphorylation (67) . In transgenic mice overexpressing CaMKII, RyRs show increased Ca 2+ spark frequency, which can be reduced by CaMKII inhibition (44) . In a rabbit heart failure model of left ventricular pressure and volume overload, there is increased CaMKII phosphorylation of RyRs. Inhibiting CaMKII in this model reduced SR leak and enhanced SR Ca 2+ content (2). Adenovirus-mediated overexpression of CaMKII in cultured adult ventricular myocytes increases (39) or inhibits (78) RyR function. Overall, these data support an important regulatory role of CaMKII in RyR function but leave open many questions about how CaMKII acts on RyR and why CaMKII appears to have both inhibitory and stimulatory actions in various models. In heart disease, it appears that CaMKII effects on RyR contribute to the phenotype of heart failure, which includes depleted SR Ca 2+ stores as well as increased arrhythmia-initiating DADs.
PLN/SERCA
CaMKII regulates Ca 2+ reuptake from the cytoplasm by the sarcoplasmic/endoplasmic reticulum Ca ATPase (SERCA), exclusively or in large part, via its effects on phospholamban (PLN). SERCA is located on the membrane of the longitudinal SR where it functions to remove intracellular Ca 2+ , resulting in cardiomyocyte relaxation. In humans and rabbits, SERCA accounts for 70% of cytoplasmic Ca 2+ removal, whereas in rats and mice it accounts for ~90% (9) . Most of the remaining cytoplasmic Ca 2+ is removed via the sodium-potassium exchanger (NCX). SERCA is tonically inhibited by PLN, which is a 52-amino acid transmembrane protein. Association of PLN with SERCA lowers the affinity for Ca 2+ ions. Phosphorylation of PLN by either PKA (at Ser 16 ) or CaMKII (at Thr 17 ) relieves SERCA of PLN's inhibitory effects, accelerating intracellular Ca 2+ removal and enhancing SR Ca 2+ content (30, 63) .
Frequency-dependent acceleration of relaxation (FDAR) is a property of cardiomyocytes caused by the acceleration of intracellular Ca 2+ removal by SERCA at increasing heart rates. From a physiological perspec-impressive therapeutic successes, but they also produce unwanted side effects, in part by targeting diverse intracellular signals linked to GPCRs. Recently, targeting of protein kinases has been considered as an alternative and potentially more biologically selective therapeutic strategy compared with GPCRs (6). CaMKII is an appealing potential target for pharmacological inhibition. CaMKII activity is upregulated in hypertrophy and heart failure (32, 88). CaMKII overexpression in transgenic mice results in impaired Ca 2+ handling, APD prolongation, heart failure, and arrhythmias (44, 76, 88) , whereas CaMKII inhibition protects against development of heart failure and arrhythmias (76, 85) .
A potential benefit of direct CaMKII inhibition may include better specificity of inhibition that reduces unwanted global effects of GPCR inhibition. For example, ␤-adrenergic receptor inhibition is associated with improved outcomes, but negative inotropic actions limit the use of these drugs in severe (class III to IV) heart failure (28, 50). In contrast, CaMKII inhibition prevents maladaptive remodeling from excessive intermittent ␤-adrenergic receptor stimulation and myocardial infarction with preservation of baseline cardiac function and contractile reserve (85) . On the other hand, continuous exposure to excessive ␤-adrenergic stimulation may induce cultured cardiomyocytes to rely on CaMKII for contractility (66) , suggesting the possibility that CaMKII inhibition could reduce mechanical function under some conditions.
There are many potential methods for inhibiting CaMKII function including developing drugs that prevent ATP binding at the catalytic domain, drugs that result in allosteric inhibitory conformational changes to CaMKII, as well as drugs that specifically prevent CaMKII binding to protein targets. Therapies that affect the CaMKII holoenzyme architecture or prevent the conformation changes necessary for autophosphorylation and Ca 2+ -independent activity may prevent excess CaMKII activity that results in heart failure and arrhythmias.
Conclusion
CaMKII is a remarkable signaling molecule that is abundant in myocardium and other excitable tissues. CaMKII targets a wide range of proteins in heart but is especially important for regulating proteins necessary for ECC. The CaMKII holoenzyme is uniquely adapted to integrate and transduce cellular Ca 2+ signals into physiological responses in heart. Under pathological stresses, CaMKII appears to be an important disease signal. The actions of CaMKII on electrical and Ca 2+ handling proteins help to explain how CaMKII can simultaneously favor heart failure and arrhythmias. Recent findings that CaMKII inhibition reduces heart failure and suppresses arrhythmias suggest that developing CaMKII inhibitory drugs may be a new therapeutic approach to these diseases. 
